RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Xijing Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Xijing Hospital空军军医大学西京医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07685704, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically and radiologically (CT/MRI) confirmed gastric or gastroesophageal junction adenocarcinoma.

    Inclusion criterion 2

  3. Neoadjuvant cohort: Clinical stage III (cT3-4aN+M0) or locally advanced unresectable (cT4bNany M0) assessed by MDT as not amenable to R0 resection, or technically resectable but with high-risk factors (e.g., bulky nodal fusion, invasion of critical structures).

    Inclusion criterion 3

  4. ECOG performance status 0-1; no contraindication to surgery.

    Inclusion criterion 7

  5. WBC > 4.0 x 10\^9/L and < 15 x 10\^9/L; ANC > 1.5 x 10\^9/L; Hb >= 90 g/L; PLT >= 100 x 10\^9/L.

    Inclusion criterion 11

    Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN.

    Inclusion criterion 12

    Creatinine <= 1.5 x ULN, or CrCl > 60 mL/min (Cockcroft-Gault).

    Inclusion criterion 13

    No anticoagulation: INR and aPTT <= 1.5 x ULN. On stable anticoagulation: maintain stable dose.

    Inclusion criterion 14

  6. History of malignancy within 5 years before screening, except those with > 90% 5-year overall survival.

    Exclusion criterion 3

    Active hepatitis B (HBV DNA >= 1 x 10\^3 copies/mL or >= 200 IU/mL), positive anti-HCV, or positive HIV.

    Exclusion criterion 13

  7. Female patients of childbearing potential must agree to contraception from ICF signing through at least 5 months after last dose and refrain from breastfeeding. Male patients must agree to contraception from first dose through at least 7 months after last dose.

    Inclusion criterion 16

    Pregnancy or breastfeeding, or planning pregnancy during the study.

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07685704, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Willing and able to provide written informed consent (ICF).
  • Histologically and radiologically (CT/MRI) confirmed gastric or gastroesophageal junction adenocarcinoma.
  • Neoadjuvant cohort: Clinical stage III (cT3-4aN+M0) or locally advanced unresectable (cT4bNany M0) assessed by MDT as not amenable to R0 resection, or technically resectable but with high-risk factors (e.g., bulky nodal fusion, invasion of critical structures).
  • Conversion cohort: Not amenable to direct surgery (e.g., invasion of adjacent organs or vessels) or with distant metastases, including liver metastases (C-GCLM type I and II), confirmed retroperitoneal lymph node metastases, or other single-organ metastases.
  • HER2-positive by IHC (3+; or 2+ with FISH testing). No time window restriction on FISH.
  • Age 18-75 years, male or female.
  • ECOG performance status 0-1; no contraindication to surgery.
  • Adequate organ function for successful abdominal surgery.
  • Life expectancy >= 3 months.
  • Laboratory parameters within 7 days before enrollment:
  • WBC > 4.0 x 10\^9/L and < 15 x 10\^9/L; ANC > 1.5 x 10\^9/L; Hb >= 90 g/L; PLT >= 100 x 10\^9/L.
  • Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN.
  • Creatinine <= 1.5 x ULN, or CrCl > 60 mL/min (Cockcroft-Gault).
  • No anticoagulation: INR and aPTT <= 1.5 x ULN. On stable anticoagulation: maintain stable dose.
  • Good compliance; able to complete protocol-specified examinations and specimen collection.
  • Female patients of childbearing potential must agree to contraception from ICF signing through at least 5 months after last dose and refrain from breastfeeding. Male patients must agree to contraception from first dose through at least 7 months after last dose.

Exclusion Criteria:

  • Synchronous or metachronous malignancies of other organs, or recurrent disease.
  • Prior systemic therapy for gastric cancer (neoadjuvant cohort).
  • History of malignancy within 5 years before screening, except those with > 90% 5-year overall survival.
  • Significant cardiopulmonary dysfunction.
  • Major surgery within 4 weeks before study treatment initiation, or anticipated major surgery during study period (excluding diagnostic procedures).
  • Severe infection within 4 weeks before study treatment initiation.
  • Prior chemotherapy or molecular targeted therapy (neoadjuvant cohort).
  • Known hypersensitivity to study drugs or excipients, or history of severe allergic reactions to monoclonal antibodies.
  • Factors affecting oral medication intake (e.g., dysphagia >= grade 2, chronic diarrhea).
  • Significant uncontrolled comorbidities that may affect protocol compliance or interpretation of outcomes.
  • Pregnancy or breastfeeding, or planning pregnancy during the study.
  • Diagnosis of immunodeficiency or receiving systemic corticosteroid (> 10 mg/day prednisone equivalent) or other immunosuppressive therapy within 2 weeks before first dose.
  • Active hepatitis B (HBV DNA >= 1 x 10\^3 copies/mL or >= 200 IU/mL), positive anti-HCV, or positive HIV.
  • Participation in another anti-tumor clinical trial within 28 days before first dose.
  • Any condition that in the investigator's judgment may lead to premature study termination (e.g., serious illness including psychiatric disorders requiring concomitant treatment, severe laboratory abnormalities, family/social factors affecting subject safety or data collection).
  • Patient or family refusal to sign informed consent.

Quoted from ClinicalTrials.gov, NCT07685704, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07685704, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07685704